PALO ALTO, Calif. / Aug 28, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be hosting an Investor Day on September 24, 2025, in New York City, NY starting at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team.
Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com. Due to limited capacity, in-person attendance is available by invitation only.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
| Last Trade: | US$54.90 |
| Daily Change: | -1.90 -3.35 |
| Daily Volume: | 2,847,437 |
| Market Cap: | US$6.850B |
September 11, 2025 September 08, 2025 September 04, 2025 August 04, 2025 July 30, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
